Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 30,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 30,000 shares of the stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $3.25, for a total transaction of $97,500.00. Following the transaction, the director owned 6,188,287 shares of the company’s stock, valued at approximately $20,111,932.75. This represents a 0.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, July 7th, Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.96, for a total transaction of $158,400.00.
• On Tuesday, June 2nd, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.68, for a total value of $110,400.00.

Recursion Pharmaceuticals Stock Up 0.3%

RXRX stock opened at $3.18 on Friday. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. The business’s 50 day simple moving average is $3.32 and its 200 day simple moving average is $3.45. Recursion Pharmaceuticals, Inc. has a 1-year low of $2.77 and a 1-year high of $7.18. The firm has a market capitalization of $1.69 billion, a PE ratio of -3.06 and a beta of 1.03.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The company had revenue of $7.67 million during the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 48.61%. During the same quarter in the prior year, the firm earned ($0.41) earnings per share. As a group, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.9 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on RXRX shares. Morgan Stanley lifted their price target on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a report on Thursday, May 14th. JPMorgan Chase & Co. lowered their price objective on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Finally, Needham & Company LLC restated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals has a consensus rating of “Hold” and an average price target of $8.10.

Recursion Pharmaceuticals News Roundup

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Genentech advanced the collaboration’s first neuroscience target into a joint early-discovery program, providing early validation of Recursion’s platform. The company also reported that REC-7735 received IND clearance, with its Phase 1/2 ZINNIA trial expected to begin in the second half of 2026. Recursion Reports Second Quarter Financial Results
• Positive Sentiment: Management highlighted upcoming clinical catalysts, including additional REC-4881 Phase 2 data in November 2026 and further Phase 1 updates for REC-1245. Recursion also emphasized that its AI-native platform produced REC-7735 rapidly, supporting the long-term technology investment case. Recursion outlines 2026 cash OpEx guidance
• Positive Sentiment: The quarterly loss narrowed year over year to $0.25 per share from $0.41, while Recursion reduced its 2026 cash operating-expense guidance to approximately $375 million, potentially improving cash-burn visibility. RXRX mixed Q2 results and Genentech milestone

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently made changes to their positions in RXRX. Handelsbanken Fonder AB grew its position in Recursion Pharmaceuticals by 90.9% during the second quarter. Handelsbanken Fonder AB now owns 207,900 shares of the company’s stock worth $763,000 after buying an additional 99,000 shares in the last quarter. 180 Wealth Advisors LLC lifted its position in Recursion Pharmaceuticals by 12.3% during the second quarter. 180 Wealth Advisors LLC now owns 190,562 shares of the company’s stock worth $699,000 after purchasing an additional 20,880 shares during the period. Bank of America Corp DE grew its stake in Recursion Pharmaceuticals by 18.2% during the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock worth $7,665,000 after buying an additional 384,486 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Recursion Pharmaceuticals by 59.4% in the 1st quarter. Janus Henderson Group PLC now owns 220,309 shares of the company’s stock valued at $675,000 after buying an additional 82,100 shares during the period. Finally, California State Teachers Retirement System increased its holdings in Recursion Pharmaceuticals by 64.0% in the 1st quarter. California State Teachers Retirement System now owns 574,637 shares of the company’s stock valued at $1,764,000 after buying an additional 224,332 shares during the period. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.